XML 48 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note 14 - Segment Information
 12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
 

14.

Segment Information

 

Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in one segment. The Company’s business is research and development of drug candidates. Costs, including supplies, outsourced development, personnel costs and other research and development costs are tracked to reported by major program. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:

 

   

Year Ended December 31,

  
   

2024

    

2023

  
   

(000's)

  

Licensing revenue

   $ 850     $ —  
                 

Personnel

     9,918       7,568  

General

     3,965       3,647  

Tovecimig

     23,177       21,824  

CTX-471

     2,879       2,846  

CTX-8371

     2,403       2,235  

Research and development

     42,342       38,120  

Personnel

     3,818       2,623  

General

     4,661       4,054  

Stock-based compensation

     6,654       5,566  

General and administrative

     15,133       12,243  

Other income

     7,250       7,869  

Net loss

   $ (49,375 )   $ (42,494 )